Medication-Associated Gynecomastia from Spironolactone
Discontinuation of spironolactone often results in regression of breast tissue within 3 months. [1] Spironolactone is associated with gynecomastia due to antiandrogenic effects. [1]
Initial Assessment and Malignancy Exclusion
Breast cancer should be suspected when the physical examination raises concern for malignancy. [1] Mammography and breast ultrasonography with biopsy should be performed when malignancy is suspected. [1] Routine testicular ultrasonography should be considered to detect nonpalpable testicular tumors. [1] Liver function testing should be performed and creatinine and thyroid-stimulating hormone should be measured as part of the initial evaluation for secondary contributors. [1]
Medication Selection Algorithm
Spironolactone discontinuation is recommended when clinically feasible because regression frequently occurs after stopping the drug. [1] Eplerenone can be considered as an alternative mineralocorticoid receptor antagonist because it has not produced similar gynecomastia effects compared with spironolactone. [1]
Treatment Initiation Thresholds and Timing
Observation with reassurance is recommended for nonmalignant gynecomastia because stopping the causative medication often leads to regression within 3 months. [1] Breast clinic referral or escalation is indicated for persistent symptoms and for higher-grade disease. [1] Surgery can be performed at any time to reduce breast tissue. [1]
Pharmacologic Therapy for Persistent or Painful Symptoms
Selective estrogen receptor modulators are reasonable options for prevention and treatment of gynecomastia in specific settings with limited-quality evidence. [1] Tamoxifen and raloxifene are reported as effective for preventing and treating gynecomastia in men receiving prostate cancer antiestrogen therapy. [1]
Surgery Indications and Considerations
Surgery is considered when symptoms persist, when disease is higher grade, or when medications cannot be tolerated. [1] Longer duration of symptoms and higher-grade disease are associated with more surgical complications. [1]
Monitoring and Avoidance of Contributing Factors
Breast enlargement and pain should be monitored after removal of the suspected medication trigger. [1] Weight loss is recommended when pseudogynecomastia is suspected. [1] Supplement use should be scrutinized because multiple marketed products have been linked to gynecomastia. [1]
Practical Reframing of Spironolactone-Induced Gynecomastia
Spironolactone-related gynecomastia should be managed as a medication-triggered adverse effect with reassessment after drug withdrawal. [1] If ongoing mineralocorticoid receptor antagonism is required, switching from spironolactone to eplerenone supports gynecomastia risk reduction compared with continued spironolactone exposure. [1]